Critics claim that drugs like semaglutide and other GLP-1s can dangerously sap away our muscle mass, but what does the ...
While GLP-1 drugs remain wildly popular and are a highly lucrative sector, data analytics firm GlobalData contends ...
To cover or not to cover? Babst Calland attorneys discuss how employers with sponsored health plans can navigate the ...
The number of Americans with type 2 diabetes and/or obesity is rising, and the entry of therapies such as glucagon-like ...
Thousands of people in Michigan who use popular weight loss drugs will soon lose their coverage for it. Blue Cross Blue ...
When it comes to the stock market, winners tend to keep winning. That's a core tenet that many investors at The Motley Fool ...
Analyzing Madrigal Pharmaceuticals' potential in the competitive NASH drug market and why it may be right for your portfolio.
Donanemab will give Eli Lilly another potential blockbuster drug at a time when it is seeing brisk sales of its Zepbound ...
Obesity drugs keep getting linked to health benefits beyond weight loss. It’s maddeningly difficult to figure out what’s ...
Some injectable treatments available in the market to treat obesity are Eli Lilly’s LLY Zepbound (tirzepatide) and Novo ...
Analysts who follow the start-up drugmaker think its stock has a chance to soar, but that doesn't mean it's right for you.